Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2014 | Pages:
202 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Endometrial Cancer - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Endometrial Cancer - Pipeline Review, H2 2014', provides an overview of the Endometrial Cancer's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Endometrial Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometrial Cancer and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Endometrial Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Endometrial Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Endometrial Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Endometrial Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Endometrial Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Endometrial Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 8 List of Figures 9 Introduction 10 Global Markets Direct Report Coverage 10 Endometrial Cancer Overview 11 Therapeutics Development 12 Pipeline Products for Endometrial Cancer - Overview 12 Pipeline Products for Endometrial Cancer - Comparative Analysis 13 Endometrial Cancer - Therapeutics under Development by Companies 14 Endometrial Cancer - Therapeutics under Investigation by Universities/Institutes 17 Endometrial Cancer - Pipeline Products Glance 18 Late Stage Products 18 Clinical Stage Products 19 Early Stage Products 20 Endometrial Cancer - Products under Development by Companies 21 Endometrial Cancer - Products under Investigation by Universities/Institutes 23 Endometrial Cancer - Companies Involved in Therapeutics Development 24 Bristol-Myers Squibb Company 24 Sanofi 25 GlaxoSmithKline plc 26 Daiichi Sankyo Company, Limited 27 Merck & Co., Inc. 28 Novartis AG 29 BioMarin Pharmaceutical Inc. 30 Eisai Co., Ltd. 31 ImmunoGen, Inc. 32 Genmab A/S 33 Exelixis, Inc. 34 AEterna Zentaris Inc. 35 Ariad Pharmaceuticals, Inc. 36 Oncothyreon Inc. 37 Critical Outcome Technologies Inc. 38 ArQule, Inc. 39 Galena Biopharma, Inc. 40 Scancell Holdings Plc 41 Oryzon Genomics S.A. 42 Acceleron Pharma, Inc. 43 Arno Therapeutics, Inc. 44 Endocyte, Inc. 45 Esperance Pharmaceuticals, Inc. 46 Pharmsynthez 47 Shenogen Pharma Group Ltd. 48 Igenica Biotherapeutics, Inc. 49 Karyopharm Therapeutics, Inc. 50 OncoHoldings, Inc. 51 Endometrial Cancer - Therapeutics Assessment 52 Assessment by Monotherapy Products 52 Assessment by Combination Products 53 Assessment by Target 54 Assessment by Mechanism of Action 58 Assessment by Route of Administration 62 Assessment by Molecule Type 64 Drug Profiles 66 zoptarelin doxorubicin - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 ixabepilone - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 lenvatinib - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 MK-2206 - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 ridaforolimus - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 dalantercept - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 cabozantinib s-malate - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 EP-100 - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 dovitinib lactate - Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 buparlisib hydrochloride - Drug Profile 90 Product Description 90 Mechanism of Action 90 R&D Progress 90 talazoparib - Drug Profile 93 Product Description 93 Mechanism of Action 93 R&D Progress 93 GALE-301 - Drug Profile 95 Product Description 95 Mechanism of Action 95 R&D Progress 95 selinexor - Drug Profile 96 Product Description 96 Mechanism of Action 96 R&D Progress 96 cridanimod - Drug Profile 98 Product Description 98 Mechanism of Action 98 R&D Progress 98 GSK-2636771 - Drug Profile 99 Product Description 99 Mechanism of Action 99 R&D Progress 99 OPB-111001 - Drug Profile 100 Product Description 100 Mechanism of Action 100 R&D Progress 100 SAR-408701 - Drug Profile 101 Product Description 101 Mechanism of Action 101 R&D Progress 101 CLR-457 - Drug Profile 102 Product Description 102 Mechanism of Action 102 R&D Progress 102 patritumab - Drug Profile 103 Product Description 103 Mechanism of Action 103 R&D Progress 103 HuMax-TF-ADC - Drug Profile 105 Product Description 105 Mechanism of Action 105 R&D Progress 105 uprosertib - Drug Profile 106 Product Description 106 Mechanism of Action 106 R&D Progress 106 vintafolide - Drug Profile 107 Product Description 107 Mechanism of Action 107 R&D Progress 107 ONT-10 - Drug Profile 110 Product Description 110 Mechanism of Action 110 R&D Progress 110 GSK-2256098 - Drug Profile 111 Product Description 111 Mechanism of Action 111 R&D Progress 111 trametinib + uprosertib - Drug Profile 113 Product Description 113 Mechanism of Action 113 R&D Progress 113 IMGN-853 - Drug Profile 115 Product Description 115 Mechanism of Action 115 R&D Progress 115 ���Pb-TCMC-Trastuzumab - Drug Profile 116 Product Description 116 Mechanism of Action 116 R&D Progress 116 ARQ-092 - Drug Profile 117 Product Description 117 Mechanism of Action 117 R&D Progress 117 onapristone ER - Drug Profile 118 Product Description 118 Mechanism of Action 118 R&D Progress 118 COTI-2 - Drug Profile 119 Product Description 119 Mechanism of Action 119 R&D Progress 119 EP-200 - Drug Profile 122 Product Description 122 Mechanism of Action 122 R&D Progress 122 AEZS-125 - Drug Profile 123 Product Description 123 Mechanism of Action 123 R&D Progress 123 ONCO-101 - Drug Profile 124 Product Description 124 Mechanism of Action 124 R&D Progress 124 (ponatinib + ridaforolimus) - Drug Profile 125 Product Description 125 Mechanism of Action 125 R&D Progress 125 Peptides to Inhibit GnRH II Receptor for Oncology - Drug Profile 126 Product Description 126 Mechanism of Action 126 R&D Progress 126 Antibody Targeting L1CAM for Ovarian and Endometrial Cancer - Drug Profile 127 Product Description 127 Mechanism of Action 127 R&D Progress 127 SNG-1153 - Drug Profile 128 Product Description 128 Mechanism of Action 128 R&D Progress 128 Monoclonal Antibody For Endometrial Cancer - Drug Profile 129 Product Description 129 Mechanism of Action 129 R&D Progress 129 Small Molecule to Inhibit AKR1C3 for Oncology - Drug Profile 130 Product Description 130 Mechanism of Action 130 R&D Progress 130 Small Molecules to Inhibit Ras for Oncology - Drug Profile 131 Product Description 131 Mechanism of Action 131 R&D Progress 131 CRC-06 - Drug Profile 132 Product Description 132 Mechanism of Action 132 R&D Progress 132 Modi-1 - Drug Profile 133 Product Description 133 Mechanism of Action 133 R&D Progress 133 SERD-2 - Drug Profile 134 Product Description 134 Mechanism of Action 134 R&D Progress 134 Endometrial Cancer - Recent Pipeline Updates 135 Endometrial Cancer - Dormant Projects 192 Endometrial Cancer - Discontinued Products 193 Endometrial Cancer - Product Development Milestones 194 Featured News & Press Releases 194 Jun 17, 2014: Galena Biopharma Completes Enrollment in GALE-301 Phase 2a Clinical Trial in Ovarian and Endometrial Cancers 194 Jun 02, 2014: Aeterna Zentaris: Poster Presented at ASCO Meeting on the Design of the Current ZoptEC Phase 3 Trial in Endometrial Cancer 194 May 22, 2014: Aeterna Zentaris: Poster to be Presented on the Design of Current ZoptEC Phase 3 Trial in Endometrial Cancer with Zoptarelin Doxorubicin at ASCO 195 May 21, 2014: Galena Biopharma to Present GALE-301 Phase 1 Data at the American Society of Clinical Oncology 50th Annual Meeting 195 Feb 04, 2014: Aeterna Zentaris: Article on Phase 2 Results for Zoptarelin Doxorubicin in Endometrial Cancer Published in the International Journal of Gynecological Cancer 196 Feb 03, 2014: Aeterna Zentaris: Presentations on Zoptarelin Doxorubicin at Upcoming International Symposium on GnRH 197 Sep 09, 2013: Arno Therapeutics Submits IMPD to French Health Authority to Initiate Phase I Trial of Onapristone in PR Positive Tumors 197 Aug 21, 2013: Arno Therapeutics Initiates Pharmacokinetic Study for Onapristone Following Regulatory Acceptance 198 Jul 31, 2013: Aeterna Zentaris: First Patient Dosed for Phase 3 Registration Trial in Endometrial Cancer with Zoptarelin Doxorubicin 198 Jun 11, 2013: Critical Outcome Technologies Announces Positive Preclinical Results Of Cancer Drug Candidiate COTI-2 Against p53 Gene Mutations 199 Appendix 201 Methodology 201 Coverage 201 Secondary Research 201 Primary Research 201 Expert Panel Validation 201 Contact Us 202 Disclaimer 202
List of Tables Number of Products under Development for Endometrial Cancer, H2 2014 12 Number of Products under Development for Endometrial Cancer - Comparative Analysis, H2 2014 13 Number of Products under Development by Companies, H2 2014 15 Number of Products under Development by Companies, H2 2014 (Contd..1) 16 Number of Products under Investigation by Universities/Institutes, H2 2014 17 Comparative Analysis by Late Stage Development, H2 2014 18 Comparative Analysis by Clinical Stage Development, H2 2014 19 Comparative Analysis by Early Stage Development, H2 2014 20 Products under Development by Companies, H2 2014 21 Products under Development by Companies, H2 2014 (Contd..1) 22 Products under Investigation by Universities/Institutes, H2 2014 23 Endometrial Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2014 24 Endometrial Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2014 25 Endometrial Cancer - Pipeline by GlaxoSmithKline plc, H2 2014 26 Endometrial Cancer - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 27 Endometrial Cancer - Pipeline by Merck & Co., Inc., H2 2014 28 Endometrial Cancer - Pipeline by Novartis AG, H2 2014 29 Endometrial Cancer - Pipeline by BioMarin Pharmaceutical Inc., H2 2014 30 Endometrial Cancer - Pipeline by Eisai Co., Ltd., H2 2014 31 Endometrial Cancer - Pipeline by ImmunoGen, Inc., H2 2014 32 Endometrial Cancer - Pipeline by Genmab A/S, H2 2014 33 Endometrial Cancer - Pipeline by Exelixis, Inc., H2 2014 34 Endometrial Cancer - Pipeline by AEterna Zentaris Inc., H2 2014 35 Endometrial Cancer - Pipeline by Ariad Pharmaceuticals, Inc., H2 2014 36 Endometrial Cancer - Pipeline by Oncothyreon Inc., H2 2014 37 Endometrial Cancer - Pipeline by Critical Outcome Technologies Inc., H2 2014 38 Endometrial Cancer - Pipeline by ArQule, Inc., H2 2014 39 Endometrial Cancer - Pipeline by Galena Biopharma, Inc., H2 2014 40 Endometrial Cancer - Pipeline by Scancell Holdings Plc, H2 2014 41 Endometrial Cancer - Pipeline by Oryzon Genomics S.A., H2 2014 42 Endometrial Cancer - Pipeline by Acceleron Pharma, Inc., H2 2014 43 Endometrial Cancer - Pipeline by Arno Therapeutics, Inc., H2 2014 44 Endometrial Cancer - Pipeline by Endocyte, Inc., H2 2014 45 Endometrial Cancer - Pipeline by Esperance Pharmaceuticals, Inc., H2 2014 46 Endometrial Cancer - Pipeline by Pharmsynthez, H2 2014 47 Endometrial Cancer - Pipeline by Shenogen Pharma Group Ltd., H2 2014 48 Endometrial Cancer - Pipeline by Igenica Biotherapeutics, Inc., H2 2014 49 Endometrial Cancer - Pipeline by Karyopharm Therapeutics, Inc., H2 2014 50 Endometrial Cancer - Pipeline by OncoHoldings, Inc., H2 2014 51 Assessment by Monotherapy Products, H2 2014 52 Assessment by Combination Products, H2 2014 53 Number of Products by Stage and Target, H2 2014 56 Number of Products by Stage and Mechanism of Action, H2 2014 60 Number of Products by Stage and Route of Administration, H2 2014 63 Number of Products by Stage and Molecule Type, H2 2014 65 Endometrial Cancer Therapeutics - Recent Pipeline Updates, H2 2014 135 Endometrial Cancer - Dormant Projects, H2 2014 192 Endometrial Cancer - Discontinued Products, H2 2014 193
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
